Close Menu

Mass General

In opening its new translational research lab, Mass General claims to be "the first and only cancer center" to attempt to molecularly profile all cancer patients that present to the facility.

Obama Ends hESC Research Restrictions, Connecticut Innovations, Helix Therapeutics, Canadian Forest Nanoproducts Network, Québec Consortium for Drug Discovery, Wisconsin Opportunity Grants, Wisconsin Emerging Industries Skills Partnership, Qatar Science & Technology Park

The hospital will use a new lab to study tumors and to try to develop individual treatments.

NHLBI in late January put out an RFP for the program, which calls for researchers to develop proteomics technologies and apply them to solve clinical puzzles. It is set to begin early next year, shortly after its current two major proteomics initiatives expire.

The deal brings to six the number of academic institutions from which Fate has licensed IP related to using small molecules to induce pluripotency in stem cells for therapeutic effect, drug discovery, and matched cell-replacement therapies.

HP will continue to work with the healthcare system to provide hardware and software for clinical genomics projects.

The Massachusetts Life Sciences Center has approved spending a combined $2.5 million of the $1 billion, 10-year Life Sciences Act to subsidize life-sci companies that hire paid college-level interns, and to fund younger researchers.

Vista has secured rights to the nanowire technology from Harvard and previous spinout Nanosys, which has, for the time being, eschewed biomedical applications for the tech in favor of nearer-term commercial opportunities.

Adding Genes to Risk Factors

Premium

In a genotype-versus-phenotype showdown, a diabetes researcher says that phenotype has better predictive power but that genetic variants show promise.

Elias Zerhouni has joined the Gates Foundation, Aushon Biosystems has named a new VP of North American Sales, Joshua LaBaer heads West to Arizona State University, and more.

Pages

23andMe is offering early customers re-testing on newer chips for a fee, Wired reports.

He Jiankui is no longer affiliated with Direct Genomics Biotechnology, the single molecule sequencing company he founded, Nikkei Asian Review reports.

Newsweek writes about the hopes for precision medicine in cancer, but also challenges getting it to patients.

In Genome Research this week: genomic architecture of glioblastoma, predictive computational approach to estimate SNP fitness, and more.